AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
171.56
-2.14 (-1.23%)
At close: Jan 17, 2025, 4:00 PM
171.60
+0.04 (0.02%)
After-hours: Jan 17, 2025, 7:12 PM EST
AbbVie Revenue
AbbVie had revenue of $14.46B in the quarter ending September 30, 2024, with 3.83% growth. This brings the company's revenue in the last twelve months to $55.53B, up 0.72% year-over-year. In the year 2023, AbbVie had annual revenue of $54.32B, down -6.44%.
Revenue (ttm)
$55.53B
Revenue Growth
+0.72%
P/S Ratio
5.46
Revenue / Employee
$1,110,660
Employees
50,000
Market Cap
303.17B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 54.32B | -3.74B | -6.44% |
Dec 31, 2022 | 58.05B | 1.86B | 3.30% |
Dec 31, 2021 | 56.20B | 10.39B | 22.69% |
Dec 31, 2020 | 45.80B | 12.54B | 37.69% |
Dec 31, 2019 | 33.27B | 513.00M | 1.57% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
Eli Lilly and Company | 40.86B |
ABBV News
- 1 day ago - Top 4 Immunology Stocks Poised For Growth In 2025 - Seeking Alpha
- 3 days ago - Income & Growth: 3 Of The Best Dividend Stocks For Any Market - Seeking Alpha
- 5 days ago - AbbVie Inc. (ABBV) J.P. Morgan 43rd Annual Healthcare Conference (Transcript) - Seeking Alpha
- 5 days ago - AbbVie to 'commit less capital' towards psychiatric drugs, CEO says - Reuters
- 5 days ago - My Dividend Stock Portfolio: $10,000 In Dividends In 2024 - 97 Holdings With 13 Buys - Seeking Alpha
- 5 days ago - Alzamend Neuro to Present at the Sequire Investor Summit - Business Wire
- 6 days ago - AbbVie Has Immense Cash Flow Potential - Seeking Alpha
- 6 days ago - Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025 - Seeking Alpha